FDA clears blood test to help assess Alzheimer’s in primary and specialty care

Clinical Takeaway: For adults ≥55 years with cognitive complaints, Roche’s newly FDA-cleared Elecsys pTau217 blood test may help primary care clinicians identify patients who are more or less likely to have Alzheimer’s-related amyloid pathology, potentially accelerating evaluation, referral, and treatment decisions without immediate reliance on PET imaging or CSF testing.

FDA has cleared Roche’s Elecsys pTau217, the first and only FDA-cleared single-biomarker blood test intended to support both rule-in and rule-out assessment of amyloid pathology associated with Alzheimer’s disease in people aged 55 years and older with signs, symptoms, or complaints of cognitive decline. Developed with Eli Lilly, the test uses a single validated set of cutoffs across both primary and specialty care settings.

Most patients with early cognitive concerns are initially seen in primary care, yet access to confirmatory Alzheimer’s testing can be limited. Traditional approaches such as amyloid PET imaging and cerebrospinal fluid testing can be costly, invasive, and difficult to obtain. Roche says the blood-based assay demonstrated high agreement with amyloid PET imaging and can be run on the company’s existing cobas laboratory platform, which is already widely deployed in U.S. clinical labs.

The test categorizes results as positive, intermediate, or negative for amyloid pathology likelihood and is intended to be used alongside clinical assessment and other diagnostic information, not as a stand-alone diagnostic tool. By helping identify patients who may need additional workup or specialist referral, the assay could streamline the diagnostic pathway and improve access to earlier Alzheimer’s evaluation.

Source: Roche. (2026 Aug 23). Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care